Literature DB >> 18704639

Long-term survival after multimodal therapy in a patient demonstrating intrahepatic cholangiocarcinoma with hilar invasion and intrahepatic metastases.

Soichiro Morinaga1, Yuji Yamamoto, Nobuhiro Sugano, Hiroo Wada, Manabu Shiozawa, Makoto Akaike, Yukio Sugimasa.   

Abstract

Cholangiocarcinoma is a therapeutically challenging malignancy. This report describes a case where the patient received multimodal therapy, including surgery, adjuvant chemoradiation therapy, and combination chemotherapy and successfully achieved long-term survival. Specifically, the patient achieved an extended complete response after combination chemotherapy with TS-1 (an orally administered drug that is a combination of tegafur, 5-chloro-2, 4-dihydroxypyridine [CDHP], and oteracil potassium [Oxo]) and cisplatin for recurrence. This result suggests that chemoradiation or combination chemotherapy regimens using oral 5-fluorouracil (5-FU) analogues might therefore be helpful in patients with this malignancy. However, further clinical trials are required.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18704639     DOI: 10.1007/s10147-007-0741-3

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  20 in total

1.  Classification of regional lymph nodes in Japan.

Authors: 
Journal:  Int J Clin Oncol       Date:  2003-08       Impact factor: 3.402

Review 2.  Cholangiocarcinoma.

Authors:  Konstantinos N Lazaridis; Gregory J Gores
Journal:  Gastroenterology       Date:  2005-05       Impact factor: 22.682

3.  [A long term survival case of advanced intrahepatic cholangiocarcinoma treated with multidisciplinary treatment].

Authors:  Toshiro Masuda; Toru Beppu; Takatoshi Ishiko; Takao Mizumoto; Seiji Hosaka; Osamu Nakahara; Hiromitsu Hayashi; Hirohisa Okabe; Tsuyoshi Yamanaka; Kazutoshi Okabe; Hiroshi Takamori; Keiichiro Kanemitsu; Masahiko Hirota; Hideo Baba
Journal:  Gan To Kagaku Ryoho       Date:  2006-11

4.  Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma.

Authors:  S Thongprasert; S Napapan; C Charoentum; S Moonprakan
Journal:  Ann Oncol       Date:  2005-02       Impact factor: 32.976

5.  Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.

Authors:  Jennifer J Knox; David Hedley; Amit Oza; Ron Feld; Lillian L Siu; Eric Chen; Mahsan Nematollahi; Gregory R Pond; Jessica Zhang; Malcolm J Moore
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

6.  Macroscopic types of intrahepatic cholangiocarcinoma: clinicopathologic features and surgical outcomes.

Authors:  Kazuhiro Hirohashi; Takahiro Uenishi; Shoji Kubo; Takatsugu Yamamoto; Hiromu Tanaka; Taichi Shuto; Hiroaki Kinoshita
Journal:  Hepatogastroenterology       Date:  2002 Mar-Apr

7.  High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1.

Authors:  Kazuhiko Hayashi; Toshihide Imaizumi; Kazumi Uchida; Hidekazu Kuramochi; Ken Takasaki
Journal:  Oncol Rep       Date:  2002 Nov-Dec       Impact factor: 3.906

8.  Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin.

Authors:  M Ducreux; P Rougier; A Fandi; M C Clavero-Fabri; A L Villing; F Fassone; L Fandi; J Zarba; J P Armand
Journal:  Ann Oncol       Date:  1998-06       Impact factor: 32.976

9.  Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival.

Authors:  H A Pitt; A Nakeeb; R A Abrams; J Coleman; S Piantadosi; C J Yeo; K D Lillemore; J L Cameron
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

Review 10.  A review and update on cholangiocarcinoma.

Authors:  Matthew J Olnes; Rodrigo Erlich
Journal:  Oncology       Date:  2004       Impact factor: 2.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.